Literature DB >> 21372196

Discontinuation of imatinib may be possible in chronic myelogenous leukemia.

Mary Kay Barton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21372196     DOI： 10.3322/caac.20110

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  2 in total

1.  Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.

Authors:  Sergej Konoplev; C Cameron Yin; Steven M Kornblau; Hagop M Kantarjian; Marina Konopleva; Michael Andreeff; Gary Lu; Zhuang Zuo; Rajyalakshmi Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Leuk Lymphoma       Date:  2012-07-09

2.  Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.

Authors:  Marie P Shieh; Masato Mitsuhashi; Michael Lilly
Journal:  Clin Med Insights Oncol       Date:  2011-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.